Related Experiment Video
Updated: Jun 23, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
469
Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients
Friedhelm Raue1,2, Karin Frank-Raue3,4
1Endocrine Practice, Heidelberg, Germany. friedhelm.raue@raue-endokrinologie.de.
Summary
Postoperative assessment of medullary thyroid carcinoma (MTC) involves staging, imaging, and monitoring calcitonin (CTN) levels to guide treatment. Management focuses on controlling disease, palliating symptoms, and improving quality of life for incurable metastatic MTC.
Area of Science:
- Oncology
- Endocrinology
- Molecular Diagnostics
Background:
- Medullary thyroid carcinoma (MTC) requires comprehensive postoperative assessment.
- Staging, including TNM and molecular markers, stratifies MTC patient risk.
- Monitoring tumor markers like calcitonin (CTN) and CEA is crucial.
Purpose of the Study:
- To outline the essential postoperative evaluation and management strategies for MTC patients.
- To detail methods for assessing residual disease, metastases, and disease progression.
- To discuss treatment options for metastatic MTC, balancing efficacy and toxicity.
Main Methods:
- Postoperative staging using TNM, Ki67, mitotic count, and RET mutation analysis.
- Serum calcitonin (CTN) and CEA level monitoring.
- Imaging modalities including CT, MRI, US, bone scintigraphy, and PET/CT.
- Utilizing RECIST criteria for assessing tumor growth rate.
Main Results:
- Low postoperative CTN levels (<150 pg/ml) indicate a favorable outcome, often confined to the neck lymph nodes.
- Elevated CTN levels (>150 pg/ml) necessitate comprehensive imaging to detect metastases.
- Sequential imaging and tumor marker doubling time help estimate MTC growth rate.
Conclusions:
- Effective management of MTC involves precise staging and monitoring.
- Treatment decisions for metastatic MTC require careful consideration of active surveillance versus systemic therapies.
- Goals include locoregional control, symptom palliation, and improved quality of life for incurable metastatic disease.
